Search PubMedSearch

PubMed · 42719397

T-SMmOTE: tweaked synthetic majority minority oversampling technique for data scarcity issue in multi omics studies.

Abstract

MOTIVATION: Multiomics data offer a rich data mine for modeling complex as well as day-to-day diseases, but their practical deployment is constrained by the limited sample availability. To this end, generating synthetic samples is a viable remedy. Extant schemes operating along this line, however, are mostly limited to augmenting the minority class in imbalanced datasets and often produce synthetic samples that lack sufficient diversity and fail to faithfully capture the underlying data distribution. As a result, the full potential of synthetic augmentation in multi-omics learning remains underexplored. The aim is to address the data scarcity problem in multi-omics domain. We propose a synthetic oversampling framework, which is dedicated to addressing overall data scarcity in multi-omics datasets and the lack of diversity in synthetic samples. Contrary to conventional methods that restrict augmentation to minority classes and rely on interpolation of two neighbors, our method generates diverse yet distribution-aligned synthetic samples by interpolating three neighbors and extends this augmentation paradigm to the majority class. The framework first balances the dataset by generating synthetic minority samples, and subsequently augments the balanced dataset by oversampling both majority and minority classes. RESULTS: Empirical evaluation on multi-omics data obtained from three heterogeneous health scenarios-inflammatory bowel disease, multi-organ dysfunction syndrome, and colorectal cancer-substantiates the utility of the proposed scheme in improving the predictive performance. The models trained on T-SMmOTE-augmented data achieve higher Matthews correlation coefficient values, along with improvedscores for both majority and minority classes. Notably, oversampling of the majority class improves the cognition of the minority class as well. We also explore the consistency of the class distributions between the original and augmented class-specific datasets. These findings confirm the capability of our scheme to learn from small, high-dimensional multi-omics datasets and highlight its potential for non-invasive disease detection. AVAILABILITY AND IMPLEMENTATION: https://github.com/payelu/TSMm.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Payel Sadhukhan, Animesh Acharjee. 2026-08-14. T-SMmOTE: tweaked synthetic majority minority oversampling technique for data scarcity issue in multi omics studies.. https://doi.org/10.1093/bioadv%2Fvbag236

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article